Communiqués Sandoz Group AG

Actions

SDZ

CH1243598427

Produits pharmaceutiques

Temps réel estimé Cboe Europe Autres places de cotation 12:40:43 21/05/2026			Varia. 5j.	Varia. 1 janv.
65,30 ^CHF	-0,88%		+0,18%	+13,42%

15/05	La Bourse suisse termine la semaine à l'équilibre ; la Fed met fin aux sanctions contre UBS et Credit Suisse	MT
15/05	Sandoz enrichit son offre d'insuline en Europe avec deux produits	AW

Communiqués

15/05	Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes	EQ
05/05	Sandoz : climate targets validated by Science Based Targets initiative (SBTi)	PU
29/04	Sandoz : Q1 - (Q1 2026 Sales Announcement)	PU
29/04	Sandoz : Q1 - (Q1 2026 Highlights)	PU
29/04	Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed	EQ
17/04	Rwanda Signs Medicines Deal With Swiss Drug Maker	AQ
15/04	Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets	EQ
13/04	Twenty years of biosimilar medicines: a milestone that continues to transform patient access worldwide Report	PU
13/04	Twenty years of biosimilar medicines: a milestone that continues to transform patient access worldwide	EQ
09/04	Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG	EQ
02/04	Sandoz : Q1 - (260401 Sandoz Aide Memoire)	PU
25/03	Samsung Bioepis And Sandoz Expand Potential Portfolios Through New Research And Development Collaborations	AQ
18/03	Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets	EQ
11/03	Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year	EQ
10/03	Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth	EQ
25/02	Sandoz : Media-release-2025-q4	PU
25/02	Sandoz : Analyst-2025-q4	PU
25/02	Sandoz : 2025-q4	PU
25/02	Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth	EQ
23/02	Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology	EQ
18/02	Sandoz : deepens renewable electricity efforts by joining two new multi buyer virtual Power Purchase Agreements	PU
18/02	Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications	EQ
14/02	Sandoz at Munich Security Conference: “Europe must start to treat essential medicines as critical security infrastructure”	PU
14/01	Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes	EQ
12/01	Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity	EQ